###### Strengths and limitations of this study

-   This study is a large sample from the Chinese National HIV Drug Resistance (HIVDR) Surveillance and Monitoring Database that was obtained from a series of cross-sectional surveys from 2003 to 2012.

-   The prevalence of injecting drug users (IDUs) in southwest China is serious; however, IDUs in Guangxi and Yunnan showed promising results from antiretroviral treatment and had fewer virological failures.

-   The outcomes of this study may not fully represent all IDUs in China.

-   Owing to the long time span covered by the data in our study, changes to prevention policies and treatment programmes may have influenced the effectiveness of the treatment.

-   Our study can only provide a reference for the diverse localities studied, with each having different epidemic and intervention situations.

Introduction {#s1}
============

Since the early 1990s, highly active antiretroviral therapy (HAART) has been used to treat HIV-infected patients worldwide, improving immune reconstitution and decreasing AIDS-related mortality.[@R1] Unfortunately, incomplete viral suppression may lead to the development of HIV drug resistance, which not only compromises therapeutic effects for an individual, but also endangers the population as a whole.[@R4]

In 2012, UNAIDS reported that injecting drug users (IDUs) worldwide were the population most at risk to be affected by HIV. Based on data from 49 countries, the rate of HIV infection of IDUs was 22 times that of the general population.[@R5] In China, where sex has becoming the main route of HIV transmission, HIV prevalence in IDUs is higher for female sex workers and men who have sex with men.[@R6] [@R7] In 2003, the 'four free one care' policy was introduced, which provided free antiretroviral treatment for all eligible HIV patients in China. According to the analysis of the 2013 HIV/STD epidemic in China, more than 278 000 patients had received the free antiretroviral treatment.[@R8] Since 2004, methadone maintenance treatment (MMT), needle exchange and harm reduction have gradually expanded in China; this has improved the adherence of IDUs to treatment and reduced HIV transmission. However, a previous smaller study showed that when compared to other patients, the proportion of virological failure among IDUs was higher.[@R9] Taking into consideration the conditions of IDUs in China, a large sample from the Chinese National HIV Drug Resistance (HIVDR) Surveillance and Monitoring Database was used to analyse and determine the prevalence of virological failure and drug resistance among IDUs receiving the first-line ART in China.

Methods {#s2}
=======

Study design and study participants {#s2a}
-----------------------------------

We collected data through the Chinese National HIVDR Surveillance and Monitoring Network, which consists of four core laboratories (National Center for AIDS/STD Control and Prevention (NCAIDS), Shanghai Municipal Center for Disease Control and Prevention (CDC), Chinese Medical University Center for AIDS Research, and Institute of Microbiology and Epidemiology of the Chinese Academy of Military Medical Sciences) and laboratories from 30 provincial CDCs.[@R10] IDUs were defined as patients who had a history of self-reported drug injection. Samples were obtained from a series of cross-sectional surveys from 2003 to 2012 on HIV drug resistance in adult patients at nationally representative ART clinics. The inclusion criteria were: (1) HIV infected IDU; (2) age ≥18 years; (3) onset of HAART between 1 January 2003 and 31 December 2011; (4) received free national first-line ART treatment; (5) consent and willingness to participate in the study.

Data collection {#s2b}
---------------

Data were collected through an interviewer-administered questionnaire. All participants provided written informed consent before participation in the study. Each participant was assigned a confidential identification number used to identify questionnaires and blood specimens. The questionnaire was administered face to face by a trained interviewer in a private room. Questionnaire questions included sociodemographic characteristics, HIV risk factors, HAART regimens and self-reported adherence measures. Demographic variables included sex, ethnicity, education level, occupation, marital status and HIV transmission route. Self-reported adherence variables included missed ART doses in the past month.

Laboratory analysis {#s2c}
-------------------

Blood specimens were collected from all participants to test CD4 cell count, HIV viral load (VL) and HIV drug resistance mutations at the baseline survey. CD4 cell counts were determined by flow cytometry in the provincial CDC offices within 24 h of collection. Plasma HIV RNA was quantified with real-time NASBA (NucliSense Easy Q, bioMerieux, France) or COBAS (Roche Applied Biosystems, Germany) according to the manufacturer\'s recommendations. Samples with VL ≥1000 copies/mL were selected for HIV drug resistance testing by using an in-house PCR.[@R9] [@R10] In order to perform HIV drug resistance mutations, HIV-1 *pol* gene (protease 1--99 amino acids and part of the reverse transcriptase 1--252 amino acids) were amplified and analysed using the Stanford HIV Drug Resistance Database (<http://hivdb.stanford.edu/>). We included mutation results that conferred low-level, intermediate-level and high-level resistance.[@R11] [@R12]

Data analysis {#s2d}
-------------

All questionnaire data were double-entered using Epidata 3.1 (The Epidata Association Odense, Denmark). Statistical Analysis System (SAS V.9.2, SAS Institute Inc, Cary, North Carolina, USA) was then used for data cleaning and analysis. Univariate logistic regression models were constructed to explore associations between virological failure, demographic characteristics, HAART regimens, adherence and CD4 data. OR and 95% CIs were calculated as well. Variables that were significant (p\<0.05) in the univariate models were used in stepwise multivariate logistic regression models and presented with AOR and 95% CIs. Owing to the large sample and according to some previous studies,[@R9] [@R10] [@R13] [@R14] p\<0.05 was defined as statistically significant, and all tests were two sided.

Results {#s3}
=======

Demographic characteristics {#s3a}
---------------------------

Of the 8556 patients in the National HIVDR Database who began treatment between 1 January 2003 and 31 December 2011, 929 IDUs matched the inclusion criteria. The demographic characteristics of the participants were shown in [table 1](#BMJOPEN2014005886TB1){ref-type="table"}. In total, 90.8% were men; the mean age was 35.7±6 years; 55.1% were ethnically Han; 60.8% had an education level of junior high school or higher; 23.4% were farmers; and more than half (65.2%) were married.

###### 

Characteristics of IDU patients receiving antiretroviral treatment in China

  Characteristics                          Number            Percentage
  ---------------------------------------- ----------------- ------------
  Total                                    929               
   Age (years): mean±SD                    35.7±6.0          
  Sex                                                        
   Male                                    844               90.8
   Female                                  85                9.2
  Ethnicity                                                  
   Han                                     512               55.1
   Minorities                              417               44.9
  Education                                                  
   Illiterate                              101               10.9
   Primary school                          263               28.3
   Junior high school                      410               44.1
   High school or more                     155               16.7
  Occupation                                                 
   Farmer                                  217               23.4
   Others                                  712               76.6
  Married                                                    
   Yes                                     606               65.2
   No                                      323               34.8
  Initial ART regimen                                        
   AZT+3TC+EFV                             88                9.5
   AZT+3TC+NVP                             323               34.8
   D4T+3TC+EFV                             86                9.3
   D4T+3TC+NVP                             305               32.8
   DDI-based regimens                      127               13.6
  ART regimen at survey                                      
   AZT+3TC+NVP/EFV                         486               52.3
   D4T+3TC+NVP/EFV                         323               34.8
   DDI-based regimen                       90                9.7
   Second-line regimens                    30                3.2
   Duration of ART (months): median, IQR   14.0, 6.0--17.8   
  Province                                                   
   Xinjiang                                306               32.9
   Yunnan                                  184               19.8
   Hunan                                   174               18.7
   Guangxi                                 122               13.1
   Sichuan                                 42                4.5
   Guizhou                                 25                2.7
   Guangdong                               19                2.1
   Shandong                                12                1.3
   Gansu                                   12                1.3
   Jiangxi                                 10                1.1
   Others                                  23                2.5

ART, antiretroviral treatment; IDU, injecting drug users.

HAART regimens and virological profiles {#s3b}
---------------------------------------

Initial HAART regimens were AZT+3TC+EFV (9.5%), AZT+3TC+NVP (34.8%), D4T+3TC+EFV (9.3%), D4T+3TC+NVP (32.8%), and DDI-based regimens (didanosine (DDI)+nevirapine (NVP) or efavirenz (EFV)) (13.6%). HAART regimens at survey were AZT+3TC+NVP/EFV (52.3%), D4T+3TC+NVP/EFV (34.8%), DDI-based regimens (9.7%) and second-line regimens (3.2%). At the time of the survey, 193 (20.8%) patients had a VL ≥1000 copies/mL. Among these participants, 175 were successfully genotyped. CRF07_BC was the most common HIV viral subtype (41.7%), followed by CRF01_AE (27.4%). Of these, 68 had detectable HIVDR mutations.

HIV drug resistance mutations {#s3c}
-----------------------------

Among the participants with HIVDR mutations, 36/68 (52.9%) patients were resistant to non-nucleoside reverse transcriptase inhibitor (NNRTIs) drugs. Fifty two of sixty eight (76.5%) patients had drug resistance to nucleoside reverse transcriptase inhibitor (NRTIs) drugs. Three of sixty eight (4.4%) patients were identified to have drug resistance to protease inhibitors (PIs). In addition, 21/68 (30.9%) patients had multidrug resistance to NNRTIs and NRTIs. The most frequent NNRTIs mutations occurred at position 103 in the RT (reverse transcriptase) region and NRTIs mutations occurred at position 184 in the RT region. PI mutations were also found at positions 47 and 46 in the PR (protease) region ([table 2](#BMJOPEN2014005886TB2){ref-type="table"}).

###### 

HIV drug resistance mutations among IDU patients with drug resistance

  -----------------------------------------------------------------------------------------------------------------------
  Antiretroviral drug                                              N (%)           HIV drug resistance mutations, N (%)
  ---------------------------------------------------------------- --------------- --------------------------------------
  Total                                                            68 (100.0)      

  *Non-nucleoside reverse transcriptase inhibitors (NNRTI, any)*   *36* (*52.9)*   K103N/R, 18 (26.5)\
                                                                                   Y181C, 8 (11.8)\
                                                                                   K101E/P/Q, 5 (7.4)\
                                                                                   G190A/Q/S, 4 (5.9)\
                                                                                   V106A/M, 3 (4.4)\
                                                                                   E138A/Q, 2 (2.9)\
                                                                                   A98G, 1 (1.5)\
                                                                                   M230L, 1 (1.5)\
                                                                                   P225H, 1 (1.5)\
                                                                                   V179D, 1 (1.5)\
                                                                                   Y188H, 1 (1.5)

  Efavirenz (EFV)\*                                                36 (52.9)       

  Nevirapine (NVP)\*                                               36 (52.9)       

  Delavirdine (DLV)                                                34 (50.0)       

  Etravirine (ETV)                                                 8 (11.8)        

  Rilpivirine (RPV)                                                2 (2.9)         

  *Nucleoside reverse transcriptase inhibitors (NRTI, any)*        *52 (76.5)*     M184I/V, 38(55.9)\
                                                                                   D67G/N, 6 (8.8)\
                                                                                   V75I/L/T, 4 (5.9)\
                                                                                   K65R, 3 (4.4)\
                                                                                   Y115F, 2 (2.9)\
                                                                                   K70E, 1 (1.5)\
                                                                                   L74V, 1 (1.5)\
                                                                                   M41L, 1 (1.5)\
                                                                                   N41L, 1 (1.5)\
                                                                                   T69IN, 1 (1.5)

  Emtricitabine (FTC)                                              50 (73.5)       

  Lamivudine (3TC)\*                                               50 (73.5)       

  Abacavir (ABC)                                                   19 (27.9)       

  Didanosine (DDI)\*                                               17 (25.0)       

  Stavudine (D4T)\*                                                12 (17.6)       

  Tenofovir (TDF)\*                                                9 (13.2)        

  Azidothymidine (AZT)\*                                           7 (10.3)        

                                                                                   

                                                                                   

                                                                                   

  *Protease inhibitors (PI, any)*                                  *3 (4.4)*       I47V, 1 (33.3)\
                                                                                   M46I, 1 (33.3)

  Tipranavir (TPV)                                                 3 (4.4)         

  Fosamprenavir (FPV)                                              2 (2.9)         

  Lopinavir (LPV)\*                                                2 (2.9)         

  Nelfinavir (NFV)                                                 2 (2.9)         

  Atazanavir (ATV)                                                 1 (1.5)         

  Darunavir (DRV)                                                  1 (1.5)         

  Indinavir (IDV)                                                  1 (1.5)         

  Saquinavir (SQV)                                                 1 (1.5)         

  *Multi-drug resistance to NNRTI and NRTI*                        *21 (30.9)*     
  -----------------------------------------------------------------------------------------------------------------------

\*Provided through the National Free Antiretroviral Treatment Program (NFATP).

Predictors for HIV virological failure {#s3d}
--------------------------------------

The factors associated with HIV virological failure were examined in univariate logistic regression models; those found to be statistically significant were included in the multivariate logistic regression model. There were six factors that remained in the final multivariate models ([table 3](#BMJOPEN2014005886TB3){ref-type="table"}). Factors positively associated with virological failure include: Ethnicity (compared to Han ethnicity: minorities AOR 1.8, 95% CI 1.3 to 2.6), education (compared to high school or greater: junior high school or less AOR 1.6, 95% CI 1.0 to 2.7), occupation (compared to other jobs: farmer AOR 1.6, 95% CI 1.1 to 2.3), self-reported missing doses in the past month (compared to not missing doses in the past month: AOR 1.6, 95% CI 1.0 to 2.5), CD4± cell count at survey (compared to CD4 ≥500 cells/mm^3^: CD4 350--499 AOR 1.7, 95% CI 0.9 to 3.3, CD4 200--349 AOR 2.2, 95% CI 1.2 to 4.1, CD4 0-199 AOR 2.9, 95% CI 1.6 to 5.2). Compared to other provinces, residence in Guangxi and Yunnan provinces was negatively associated with virological failure (AOR 0.4, 95% CI 0.2 to 0.6).

###### 

Factors associated with HIV viral suppression failure (viral load ≥1000 copies/mL) among IDU patients receiving antiretroviral treatment in China

  -----------------------------------------------------------------------------------------------------------------------------
  Variable                         Number   Viral suppression\   Crude OR (95% CI)   p Value   Adjusted OR (95% CI)   p Value
                                            Failure N (%)                                                             
  -------------------------------- -------- -------------------- ------------------- --------- ---------------------- ---------
  Total                            929      193 (20.8)                                                                

  Age (years)                                                                                                         

   \<35                            436      95 (21.8)                                                                 

   ≥35                             493      98 (19.9)            0.9 (0.6 to 1.2)    0.47                             

  Sex                                                                                                                 

   Male                            844      174 (20.6)                                                                

   Female                          85       19 (22.4)            1.1 (0.6 to 1.9)    0.71                             

  Ethnicity                                                                                                           

   Han                             512      85 (16.6)                                                                 

   Minorities                      417      108 (25.9)           1.8 (1.3 to 2.4)    \<0.01    1.8 (1.3 to 2.6)       \<0.01

  Education                                                                                                           

   High school or more             155      23 (14.8)                                                                 

   Junior high school or less      774      170 (22.0)           1.6 (1.0 to 2.6)    0.04      1.6 (1.0 to 2.7)       0.04

  Occupation                                                                                                          

   Others                          712      133 (18.7)                                                                

   Farmer                          217      60 (27.6)            1.7 (1.2 to 2.4)    \<0.01    1.6 (1.1 to 2.3)       0.02

  Married                                                                                                             

   No                              323      70 (21.7)                                                                 

   Yes                             606      123 (20.3)           0.9 (0.7 to 1.3)    0.62                             

  CD4 cell counts before ART                                                                                          

   0--199                          642      123 (19.2)                                                                

   200--349                        266      63 (23.7)            1.3 (0.9 to 1.8)    0.12                             

   ≥350                            21       7 (33.3)             2.1 (0.8 to 5.3)    0.12                             

  Duration of ART (months)                                                                                            

   0--12                           413      77 (18.6)                                                                 

   \>12                            516      116 (22.5)           1.3 (0.9 to 1.7)    0.15                             

  Initial ART regimen                                                                                                 

   AZT+3TC+NVP/EFV                 411      97 (23.6)                                                                 

   D4T+3TC+NVP/EFV                 391      70 (17.9)            0.7 (0.5 to 1.0)    0.05                             

   DDI-based regimen               127      26 (20.5)            0.8 (0.5 to 1.4)    0.46                             

  ART regimen at survey                                                                                               

   AZT+3TC+NVP/EFV                 486      116 (23.9)                                                                

   D4T+3TC+NVP/EFV                 323      49 (15.2)            \<0.01                                               

   DDI-based regimen               90       20 (22.2)            0.74                                                 

   Second-line regimens            30       8 (26.7)             0.73                                                 

  Missed doses in the past month                                                                                      

   No                              794      153 (19.3)                                                                

   Yes                             135      40 (29.6)            1.8 (1.2 to 2.7)    \<0.01    1.6 (1.0 to 2.5)       0.03

  CD4 cell counts at survey                                                                                           

   ≥500                            140      16 (11.4)                                                                 

   350--499                        176      34 (19.3)            1.9 (1.0 to 3.5)    0.06      1.7 (0.9 to 3.3)       0.11

   200--349                        285      66 (23.2)            2.3 (1.3 to 4.2)    \<0.01    2.2 (1.2 to 4.1)       \<0.01

   0--199                          328      77 (23.5)            2.4 (1.3 to 4.2)    \<0.01    2.9 (1.6 to 5.2)       \<0.01

  Time of starting ART (year)                                                                                         

   2003--2007                      528      103 (19.5)                                                                

   2008--2011                      401      90 (22.4)            1.2 (0.9 to 1.6)    0.27                             

  Province                                                                                                            

   Others                          623      158 (25.4)                                                                

   Guangxi and Yunnan              306      35 (11.4)            0.4 (0.3 to 0.6)    \<0.01    0.4 (0.2 to 0.6)       \<0.01
  -----------------------------------------------------------------------------------------------------------------------------

ART, antiretroviral treatment.

Sensitivity analysis {#s3e}
--------------------

[Table 4](#BMJOPEN2014005886TB4){ref-type="table"} presents factors associated with HIV viral suppression failure at the time of starting ART from 2003 to 2007 and from 2008 to 2011, respectively. Only residence of Guangxi and Yunnan provinces was observed to be at lower risk than that in other provinces during 2003 and 2007 (OR=0.4, 95% CI 0.2 to 0.6, p\<0.01) after adjusting for the initial ART regimen, ART regimen at survey, self-reported missing doses in the past month, and CD4 cell counts before ART. During 2008 and 2011, four factors were associated with virological failure, including province. Patients who were more likely to be virological failure were minorities (OR=2.3, 95% CI 1.3 to 4.0, p\<0.01), farmers (OR=2.1, 95% CI 1.2 to 3.8, p=0.01), CD4 200--349 or 0--199 (OR=3.2, 95% CI 1.3 to 7.9, p=0.01 and OR=4.1, 95% CI 1.6 to 10.3, p\<0.01) and residence of Guangxi and Yunnan provinces was a protective factor (OR=0.3, 95% CI 0.1 to 0.8, p=0.01).

###### 

Multivariate analysis of factors associated with HIV viral suppression failure among IDU patients receiving antiretroviral treatment in China from 2003 to 2007 and 2008 to 2011

                              Adjusted OR (95% CI)   
  --------------------------- ---------------------- -------------------
  Ethnicity                                          
   Han                                               
   Minorities                 --                     2.3 (1.3 to 4.0)
  Occupation                                         
   Others                                            
   Farmer                     --                     2.1 (1.2 to 3.8)
  CD4 cell counts at survey                          
   ≥500                                              
   350--499                                          
   200--349                   --                     3.2 (1.3 to 7.9)
   0--199                     --                     4.1 (1.6 to 10.3)
  Province                                           
   Others                                            
   Guangxi and Yunnan         0.4 (0.2 to 0.6)       0.3 (0.1 to 0.8)

IDU, injecting drug users.

Discussion {#s4}
==========

In this study, we analysed HIVDR data to evaluate the prevalence and risk factors of virological failure among IDUs at the national level. Our findings show that among 929 IDUs receiving free first-line ART, 20.8% had virological failure (VL ≥1000 copies/mL), which is higher than the outcomes of previous surveillance studies among other patient populations in China.[@R9] [@R13] [@R14] This suggests that treatment among IDUs has been less effective than in other high-risk populations, indicating a need for improved interventions.

Of the 193 patients who experienced failed viral suppression, 175 were successfully genotyped and 68 were identified as having drug resistance mutations. The prevalence of HIVDR among patients with virological failure was 38.9% (68/175), which suggested that HIVDR was one of the most important factors associated with virological failure, and further researches should be focused on other potential factors. 36 (52.9%) had NNRTI mutations, 52 (76.5%) had NRTI mutations and 3 (4.4%) had PI mutations. In addition, 21 (30.9%) were resistant to dual-class drugs. Similar to other studies in China, K103N/R and M184I/V were the most common NNRTI and NRTI mutations, respectively.[@R9] [@R13] Since three patients had detectable drug resistance to PIs, drugs such as second-line regimens should be used judiciously.

Our study found that minorities, people with junior high school or lower education levels and farmers were the three sociodemographic factors associated with virological failure. IDUs are more commonly found in southwest China, where there is an abundant multiethnic presence. Owing to sparser population distributions and lower income levels province-wide, these people generally received lower levels of education.[@R15] In addition, traditional cultures and religions may pose obstacles to efficient implementation of CDC-based interventions.[@R16] Similarly, most HIV-infected farmers live in rural areas, where income levels were low and healthcare infrastructure is poor, which compromises ART administration; this is corroborated by another research study conducted at three sentinel surveillance sites in China.[@R14] Thus, efforts should be carried out in order to raise awareness, strengthen health education and train doctors at villages and townships regularly; supplemental policies should aim to improve income and healthcare infrastructure in rural areas.

Poor ART adherence was another risk factor in our study, with 135 (14.5%) patients having reported missing doses in the past month, which was higher than that of other studies in China.[@R9] [@R10] [@R13] Except for one study from Indonesia which showed that adherence to ART was no different between IDUs and non-IDUs,[@R17] some international studies have found that IDUs tend to have lower ART adherence rates than non-IDUs.[@R18] [@R19] Non-adherence is associated with depression, a lack of stable relationships and active drug injection.[@R20] Good adherence can promise suppression of plasma HIV RNA and utilise the optimum effectiveness of the ART therapy.[@R23] Several international studies have focused on strategies to improve adherence, including behavioural interventions, social support,[@R24] directly administered antiretroviral therapy (DAART)[@R25] and MMT.[@R26] These studies have found that drug adherence education should be part of the rehabilitation treatment programme for IDUs as well as a further expansion of health services.

Finally, when compared to other provinces, a lower proportion of IDUs in Guangxi and Yunnan experienced virological failure. IDUs are the main high-risk population for HIV infection in Guangxi, Yunnan and Xinjiang; however, in our study of 306 patients from Xinjiang, 87 (28.4%) had virological failure, of which 85 were successfully genotyped and 28 were found to have drug resistance. This finding indicated that Xinjiang had worse effectiveness of treatment, which was corroborated by a previous study showing that patients from Xinjiang were 12.6 times more likely to develop virological failure when compared to those from Guangxi and Yunnan.[@R13] Of the 306 patients from Guangxi and Yunnan, 28 (9.2%) had missed doses in the past month, compared to 107 (17.2%) in other provinces. This supports the hypothesis that achieving good adherence is one of the most effective means to viral suppression. Similarly, a study in Guangxi reported that of the 120 patients receiving antiretroviral treatment, 113 (94.2%) took their medicine on time. The Guangxi CDC has a series of standard measurement protocols to supervise patient adherence: strict regulation of HIV drugs, regular follow-ups, treatment of opportunistic infections and strongly prioritised use of first-line regimens.[@R29] Large-scale ART treatment was implemented in Yunnan province in 2004; patients receiving free antiretroviral treatment in Yunnan had better survival effects.[@R30] In our study, the prevalence of virological failure among IDUs in Yunnan was low, which was supported by the results of local research.[@R31]

After MMT was implemented nationwide in 2004, the prevalence of HIV infection among IDUs was better controlled.[@R6] Many studies have shown that MMT is a cost-effective intervention to scale up acceptance and adherence to HAART and improve the effectiveness of therapy among IDUs.[@R16] [@R26] [@R27] However, adherence to MMT is itself associated with age, stable employment, alcohol abuse and coverage of ART.[@R32] [@R33] Hence, more strategies are needed to examine improving MMT retention.

Through the sensitivity analysis, some details would be presented. Before 2008, province was the only factor associated with virological failure; however, in addition to province, three more factors were found to be significantly associated with virological failure after 2008: ethnicity, occupation and CD4 cell counts at survey. Enlarging the sample size is an effective way to reduce biases and after combining the several cross-sectional surveys, education and self-reported missing doses in the past month were included into the final multivariate logistic regression models.

This study has several limitations. First, the data in our study was from the Chinese National HIVDR Surveillance and Monitoring Network, which may or may not fully represent all IDUs in China. Second, the study sample included patients starting antiretroviral treatment from 2003 to 2011, during which period prevention policies and treatment programmes have undergone many significant changes that have most likely influenced treatment efficacy. Lastly, our study provided a systematic examination of the treatment outcomes of IDUs in China. However, as the epidemic and intervention situations differ across diverse localities, intervention and prevention measures should be tailored differently as well.

It has been more than 10 years since the China\'s National Free Antiretroviral Treatment Program (NFATP) was put into effect in 2003. During this time span, this programme has matured and improved and, as a result, more and more HIV-infected patients have gained access to antiretroviral therapy; this has brought the HIV/AIDS epidemic under control. The implementation of NFATP has had some successful examples, such as Guangxi and Yunnan, with success in dealing with antiretroviral treatment among IDUs; however, poor adherence to treatment is still a key problem, which has led to the high rate of failure of viral suppression among IDUs. More research is needed in order to explore how to improve the adherence of IDUs.
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